Boston Scientific (NYSE:BSX) Stock Gets Price Target Trim from Needham & Company LLC

Boston Scientific (NYSE:BSX) had its price objective cut by Needham & Company LLC from $57.00 to $48.00 in a report issued on Wednesday, MarketBeat Ratings reports. They currently have a buy rating on the medical equipment provider’s stock.

Other analysts have also issued research reports about the stock. Oppenheimer reduced their price target on shares of Boston Scientific from $85.00 to $65.00 and set an “outperform” rating on the stock in a research report on Monday, September 21st. The Goldman Sachs Group lowered their price objective on shares of Boston Scientific from $71.00 to $57.00 and set a “buy” rating for the company in a research report on Tuesday, July 14th. Wells Fargo & Company cut their target price on Boston Scientific from $50.00 to $48.00 and set an “equal weight” rating for the company in a research note on Wednesday, September 23rd. Barclays upgraded Boston Scientific to a “hold” rating in a research note on Wednesday, October 7th. Finally, Canaccord Genuity Group reduced their target price on Boston Scientific from $70.00 to $66.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and an average target price of $61.43.

Boston Scientific Trading Down 1.8%

BSX opened at $41.93 on Wednesday. Boston Scientific has a twelve month low of $39.57 and a twelve month high of $105.65. The company has a 50-day simple moving average of $44.78 and a 200 day simple moving average of $56.88. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $60.77 billion, a price-to-earnings ratio of 13.38, a P/E/G ratio of 1.05 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.73. The firm had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. Boston Scientific had a net margin of 16.62% and a return on equity of 18.73%. The business’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.75 earnings per share. Analysts predict that Boston Scientific will post 3.17 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Michael F. Mahoney acquired 186,240 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The stock was acquired at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the purchase, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director David C. Habiger acquired 2,100 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The stock was bought at an average cost of $47.59 per share, with a total value of $99,939.00. Following the purchase, the director owned 17,160 shares in the company, valued at $816,644.40. The trade was a 13.94% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders bought 189,522 shares of company stock worth $9,157,810. 0.34% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in shares of Boston Scientific during the second quarter valued at about $5,534,781,000. Primecap Management Co. CA bought a new stake in shares of Boston Scientific during the second quarter worth about $2,156,233,000. Jupiter Topco LLC acquired a new position in shares of Boston Scientific in the second quarter valued at approximately $803,357,000. Bank of America Corp DE acquired a new position in shares of Boston Scientific in the second quarter valued at approximately $556,026,000. Finally, Legal & General Group Plc bought a new position in Boston Scientific in the 2nd quarter valued at approximately $431,890,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific exceeded third-quarter earnings expectations, while management continues to support its long-term growth strategy. An eight-day cyber outage reduced quarterly sales by approximately $150 million, suggesting some of the impact may be temporary. Boston Scientific: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Some analysts still see upside: Robert W. Baird raised its price target to $51, while UBS, BTIG Research and Sanford C. Bernstein retained buy or outperform-equivalent ratings, although each lowered its target. Analysts Revise Forecasts After Q3 Results
• Neutral Sentiment: Barclays and Wells Fargo both maintain equal-weight ratings with $45 price targets, indicating limited expected upside from current levels and a wait-and-see stance.
• Negative Sentiment: Boston Scientific cut its fiscal 2026 guidance below analyst expectations, and its fourth-quarter outlook points to weaker sales. Management expects full-year organic revenue growth of about 4%, while analysts see growth challenges extending into 2027. BSX Q3 Earnings Call Flags Growth Challenges
• Negative Sentiment: The cyber incident, weakness in electrophysiology and WATCHMAN heart-device products, and pricing pressure in China are raising concerns about near-term revenue growth and execution. Boston Scientific Faces Cyber Incident and Product Pressures
• Negative Sentiment: Several firms downgraded the stock, including TD Cowen, JPMorgan, Oppenheimer and Needham. TD Cowen cut its rating to hold and reduced its target from $56 to $46, while Zacks added BSX to its Strong Sell list. New Strong Sell Stocks for October 30th
• Negative Sentiment: Relative to Intuitive Surgical, Boston Scientific is viewed as having weaker earnings momentum and less attractive near-term growth, adding competitive pressure to the investment case. Intuitive Surgical vs. Boston Scientific

About Boston Scientific

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.